Inhibition of tumor implantation at sites of trauma by plasminogen activators.
The authors report on the influence of plasminogen activators (PA) on implantation of TA3Ha mammary tumor cells in the healing hepatic wounds of syngeneic strain A mice. Intravenously injected TA3Ha cells, although they rarely metastasize to the liver, formed tumors in the hepatic wounds of a significant percent (42%, P less than 0.0001) of mice. The frequency of tumor formation declined as the interval between surgery and tumor cell inoculation was increased. Furthermore, preexposure of cells to fibrinogen, fibronectin, laminin, or peptides containing the arginine-glycine-aspartic acid-serine residues dramatically reduced the frequency of tumor formation in the hepatic wounds. These results indicate that TA3Ha cells interact with fibrinogen-related proteins in the wound to aid their attachment and growth. Because these proteins are susceptible to digestion by plasmin, PA were used in this study to examine whether administration of these drugs to the mice would modulate tumor formation in the liver wounds. Among the PA tested, human plasmin B-chain-streptokinase complex (B-SK) and recombinant tissue plasminogen activator (t-PA) inhibited tumor implantation in a dose-related manner. Administration of 900 units (U) of B-SK or 3300 U of t-PA per mouse reduced the frequency of tumor formation from 42% to 0% (P = 0.02) and 11% (P = 0.02), respectively. The B-SK was complexed with p-nitrophenyl-p-guanidinobenzoate; it did not activate the plasminogen or inhibit tumor formation in the hepatic wounds. Although urokinase activated the plasminogen, it did not inhibit tumor implantation in the hepatic wound. Heparin, an anticoagulant that prevents conversion of fibrinogen to fibrin without being fibrinolytic, had no influence on tumor formation in the hepatic wounds. The PA can generate plasmin that digests the cell attachment proteins in wounds and consequently inhibits tumor cell attachment.
Murthy
M S
MS
Cell Biology Laboratory, Evanston Hospital, IL 60201.
Summaria
L J
LJ
Miller
R J
RJ
Wyse
T B
TB
Goldschmidt
R A
RA
Scanlon
E F
EF
D000230:Adenocarcinoma / Q000628:therapy*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005343:Fibrinolytic Agents / Q000493:pharmacokinetics / Q000494:pharmacology; D006207:Half-Life; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control*; D051379:Mice; D010958:Plasminogen / Q000493:pharmacokinetics / Q000494:pharmacology; D010960:Plasminogen Activators / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D013300:Streptokinase / Q000493:pharmacokinetics / Q000494:pharmacology; D010959:Tissue Plasminogen Activator / Q000494:pharmacology; D014945:Wound Healing / Q000187:drug effects
D004338:Drug Combinations; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C049423:streptokinase-plasminogen complex; D010958:Plasminogen; D013300:Streptokinase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator